AYTU BioPharma, Inc. logo

AYTU BioPharma, Inc. (AYTU) Q2 2024 Annual Earnings

AYTU·Reported September 26, 2024·After market close

AYTU BioPharma, Inc. reported Q2 2024 revenue of $18.0M, missed analyst consensus of $18.3M by $324.0K. Diluted EPS came in at $-0.82, missed the $-0.45 consensus by $0.37.

Revenue
$18.0Mmissed by $324.0K
Consensus: $18.3M
Diluted EPS
$-0.82missed by $0.37
Consensus: $-0.45
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0001437749-24-030062

Financial Snapshot

Trailing eight quarters through Q2 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q2 2024 Earnings FAQ

Common questions about AYTU BioPharma, Inc.'s Q2 2024 earnings report.

AYTU BioPharma, Inc. (AYTU) reported Q2 2024 earnings on September 26, 2024 after market close.

AYTU BioPharma, Inc. reported revenue of $18.0M and diluted EPS of $-0.82 for Q2 2024.

Revenue missed the consensus estimate of $18.3M by $324.0K. EPS missed the consensus estimate of $-0.45 by $0.37.

You can read the 10-K periodic report (0001437749-24-030062) directly on SEC EDGAR. The filing index links above go to sec.gov.